Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Larena has a portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This pending matter is located in 1 distinct art unit. This indicates a specific biological or pharmaceutical application within the company's technological interests. This concentration indicates a strategic emphasis on a particular technical niche within the Biotechnology & Pharmaceuticals sector.
The examination is being handled by 1 distinct examiner. MCKNIGHT, CIARA A is the busiest examiner for this portfolio, handling 1 pending office action. This shows that the current workload is entirely managed by a single examiner. The use of 1 distinct examiner suggests a centralized review process where all communication is directed through this official, which simplifies the management of the portfolio.
With 1 pending office action and 1 distinct examiner, the prosecution profile is very narrow. Practitioners can observe that the 1 distinct art unit involved is the only area where the company currently has active patent office proceedings. Since MCKNIGHT, CIARA A handles 1 pending office action, the outcome depends on this individual's interpretation of the claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKNIGHT, CIARA A | 1 | 61.5% | +40.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17780336 | METHOD OF LYOPHILIZATION OF A CRYOGENIZED CELLULAR COMPOSITION CONTAINING DISSOLVED GAS | MCKNIGHT, CIARA A | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17780336 | METHOD OF LYOPHILIZATION OF A CRYOGENIZED CELLULAR COMPOSITION CONTAINING DISSOLVED GAS | MCKNIGHT, CIARA A | 1656 | §103 | Non-Final OA | — | Pending | May 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLarena has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ciara A Mcknight has the most, with 1 of Larena's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
